An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part Two

Abstract

Experienced clinicians and academics from the International MAOI Expert Group comment on questions of interest concerning monoamine oxidase inhibitor (MAOI) pharmacotherapy for depression. These comments in this Part Two of the Expert Roundtable Discussion emphasize good pharmacological practice, starting with a low dose and progressing slowly and only changing one element at a time. Issues related to augmentation and drug combinations are also mentioned, including comments about the safety of ketamine. The special ability of MAOIs to improve dopamine function is highlighted, especially in relation to melancholic and psychotic depression. [ Psychiatr Ann . 2023;53(8):364–369.]